By combining transcriptome analysis with network pharmacology analysis, we demonstrated that the therapeutic mechanism of XYS in NASH-related liver fibrosis involves the regulation of STAT3, NFκB, and PPARγ and their downstream genes and the intervention of the ECM, inflammation, and metabolism. This evidence concerns the gene STAT3 and metabolic dysfunction-associated steatohepatitis.